Thermo Fisher Scientific Human TRAIL Receptor-1 (soluble) Recombinant Protein, PeproTech

Applications

Tested Dilution

Publications

Functional Assay (Functional)

Assay-dependent

-

Product Specifications

Species

Human

Expression System

E. coli

Amino acid sequence

SGTGAAAATP SKVWGSSAGR IEPRGGGRGA LPTSMGQHGP SARARAGRAP GPRPAREASP RLRVHKTFKF VVVGVLLQVV PSSAATIKLH DQSIGTQQWE HSPLGELCPP GSHRSERPGA CNRCTEGVGY TNASQQLFAC LPCTACKSDE EERSPCTTTR NTACQCKPGT FRNDNSAEMC RKCSTGCPRG MVKVKDCTPW SDIECVHKES GNGHN

Molecular weight

22.7 kDa

Class

Recombinant

Type

Protein

Purity

≥ 98% by SDS-PAGE gel and HPLC analyses.

Endotoxin concentration

<1 EU/µg

Activity

Measured by its ability to inhibit apoptosis in LN-18 cells. The expected ED50 for this effect is 0.4 -0.5 ug/ml.

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Lyophilized

Purification

purified

Contains

no preservative

Storage conditions

-20°C

Shipping conditions

Ambient

Product Specific Information

Recombinant Human soluble TRAIL Receptor-1/DR4 is a 22.7 kDa protein (215 amino acid residues) consisting of the TNFR homologous, cysteine-rich portion of the extracellular domain.

This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis

Target Information

TRAIL-R1 (CD261, DR4) is a type I transmembrane protein, also called TRAIL receptor 1. The ligand for this DR4 death receptor has been identified and termed TRAIL, which is a member of the TNF family. DR4, as many other receptors (Fas, TNFR1, etc.), mediates apoptosis and NF kappaB activation in many cells and tissues. Apoptosis, a programmed cell death, is a operating process in normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by coupled of certain cytokines (TNF family - TNF, Fas ligand) and their death domain containing receptors (TNFR1, Fas receptor).

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.